RxDoctor Payments Data

Jonathan Koff, MD

Pulmonary Disease · New Haven, CTNPI 1104040401

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $9,592 of the $15,208 with a category attached, or 63.1%. Actelion Pharmaceuticals, Ltd accounts for 81.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $12,561 and has fallen 99.8% since, to $28 in 2025.

$15,208in general payments, 2019–2025

Across 22 payments — averaging $691.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals, Ltd$12K
  • Mylan Specialty L.p.$2K
  • Pentax Of America, Inc.$500
  • AstraZeneca$128
  • Vertex$28
  • Gilead$20
$1,105,344in research payments, 2019–2025

Across 24 payments — averaging $46,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$906K
  • Jazz Pharmaceuticals Inc.$64K
  • Takeda Pharmaceuticals U.S.A., Inc.$56K
  • Omeros Corporation$33K
  • Regeneron$33K
  • Amgen$14K

What the payments were for

  • Consulting fees$5,39035%
  • Travel & lodging$9,59263%
  • Food & beverage$2051%
  • Education$200%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,208 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,480
Medicare patients
86
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft48$1,722,500
KalydecoIvacaftor14$376,526
Azithromycin17$380
Omeprazole14$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta, Kalydeco$28$2,099,02662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →